| abstract |
Disclosed is the use of selective imidazoline receptor agonists, particularl y moxonidine, rilmenidine, LNP-509, S-23515, PMS-812, PMS-847, and BU-98008, a nd the physiologically acceptable salts thereof, for the production of pharmaceutical preparations used for treating and/or preventing functional disturbances and/or diseases in larger mammals or humans, which require inhibition or a reduction in the activity of proteins that regulate the intracellular pH value and belong to the superfamily of bicarbonate transporters, particularly diseases which affect the bones as a result of an undesired bone resorption level, especially osteoporosis, diseases of the gastrointestinal tract, especially gastric ulcers, and neural and/or neuropsychiatric diseases that are related to a pathologically modified, preferably an increased, neural activity, preferably depression, Alzheimer's , eating disorders, and schizophrenia. |